Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kyowa Kirin Co., Ltd.
  6. Summary
    4151   JP3256000005

KYOWA KIRIN CO., LTD.

(4151)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
3765 3775 3830 3760 3780 Last
705800 715100 696100 571000 994300 Volume
+1.62% +0.27% +1.46% -1.83% +0.53% Change
Financials
Sales 2021 351 B 3 187 M 3 187 M
Net income 2021 52 504 M 476 M 476 M
Net cash position 2021 296 B 2 683 M 2 683 M
P/E ratio 2021 38,8x
Yield 2021 1,22%
Sales 2022 378 B 3 432 M 3 432 M
Net income 2022 63 170 M 573 M 573 M
Net cash position 2022 315 B 2 862 M 2 862 M
P/E ratio 2022 31,8x
Yield 2022 1,33%
Capitalization 2 031 B 18 416 M 18 421 M
EV / Sales 2021 4,94x
EV / Sales 2022 4,53x
Nbr of Employees 5 423
Free-Float 45,8%
More Financials
Company
Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of... 
Sector
Pharmaceuticals
Calendar
06/29
More about the company
Ratings of Kyowa Kirin Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about KYOWA KIRIN CO., LTD.
06/07MEI Pharma, Kyowa Kirin Begins Expanded Phase 2 Study of Investigational Canc..
MT
06/02Nikkei 225 Gains 0.5% on Vaccination Outlook, Softer Yen
MT
06/01Today on Wall Street: New challenges ahead for markets
06/01Amgen, Kyowa Kirin to Co-Develop, Commercialize Atopic Dermatitis Treatment K..
MT
05/20MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at Americ..
AQ
05/11CERECORá : COVID-19 Drug Gets FDA Fast Track Designation
MT
05/10KYOWA KIRINá : Receives Positive CHMP Opinion for the Self-administration of CRY..
BU
04/14Ardelyx Japanese Partner Starts Late-Stage Trials of Tenapanor to Treat High ..
MT
04/14MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Folli..
AQ
04/13Kyowa Kirin Initiates Phase 3 Clinical Studies of Tenapanor (KHK7791) for Hyp..
AQ
04/13MEI PHARMAá : Kyowa Kirin Complete Enrollment in Phase 2 Trial of Follicular Lym..
MT
03/31KYOWA KIRINá : Matters Concerning Controlling Shareholders
PU
03/29Cerecor Expands Licensing Rights for Rare Disease Antibody CERC-002
MT
03/25TWIST BIOSCIENCEá : Partners With Kyowa Kirin Unit to Discover Novel Antibodies ..
MT
03/24KYOWA KIRINá : to Issue Shares Worth Nearly $2 Million as Stock Compensation to ..
MT
More news
News in other languages on KYOWA KIRIN CO., LTD.
06/02MÄRKTE ASIEN/Starke BIP-Daten schieben Sydney auf Rekordhoch
06/02MÄRKTE ASIEN/Uneinheitlich - Starke BIP-Daten schieben Sydney an
06/01Hoy en Wall Street: Nuevos retos para los mercados
06/01WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
05/14IRW-PRESS : Entheon Biomedical Corp.: Entheon Biomedical Corp. informiert über N..
More news
Chart KYOWA KIRIN CO., LTD.
Duration : Period :
Kyowa Kirin Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KYOWA KIRIN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 3 988,18 JPY
Last Close Price 3 780,00 JPY
Spread / Highest target 29,6%
Spread / Average Target 5,51%
Spread / Lowest Target -23,3%
EPS Revisions
Managers and Directors
NameTitle
Masashi Miyamoto President, CEO & Representative Director
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Nobuo Hanai Chairman
Mitsuo Satoh Executive Officer, GM-Research & Development
Kentaro Uryu Independent Outside Director
Sector and Competitors